USPTO serial 97873713
BIOMARK
Reviewed by CopyMark Law Group
Status 654
- Filing date
- Status date
- Registration date
- —
- Examiner
- CHUNG, ABBIE
- Law office
- TMO LAW OFFICE 115
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with BIOMARK?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Dianne M. Smith-Misemer
Dianne M. Smith-Misemer HOVEY WILLIAMS LLP10801 MASTIN BOULEVARD, SUITE 1000OVERLAND PARK, KS 66210UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Antibody reagents for in vitro diagnostic use for medical purposes; diagnostic kits consisting of monoclonal antibodies, buffers, and reagents for in vitro diagnostic use for medical purposes; medical diagnostic antibody reagents for use in medical imaging; diagnostic kits consisting of monoclonal antibodies, buffers and reagents for specialized medical Raman spectrometry to monitor toxicity of drugs for medical purposes, for use in disease testing, for testing of bodily fluids for use in disease detection, namely, cancer, for screening the acetylated form of Amantadine in body fluids and human tissues samples, for use in the early detection of cancer by detecting and analyzing the levels of Spermine/Spermidine N-Acetyl Transferase (SSAT) in human tissue samples; medical diagnostic assays for testing bodily fluids in drug screening applications, namely, assays for determining the efficacy of anti-cancer drugs; medical diagnostic assays for testing bodily fluids that test for the presence and effects of drug candidates in the body; drug testing kits comprised of medial diagnostic reagents and assays for testing body fluids; medical diagnostic reagents and assays for the analysis of body fluids; diagnostic biomarker reagents for medical purposes | ACTIVE | — |
| 042 | Providing an interactive web site featuring technology that enables users to enter, access, track, store, monitor, analyze and generate health and medical information and reports | ACTIVE | — |
| 044 | Medical testing of a biological sample taken from a patient for diagnostic purposes in the field of oncology; medical testing of a biological sample taken from a patient for medical screening purposes in the field of oncology; providing medical evaluation to assess and measure response to cancer treatment; medical analysis services relating to the treatment of cancer patients to help healthcare professionals determine the effectiveness of treatments and to revise future treatments; medical diagnostic testing, monitoring and reporting services relating to disease recurrence and progression in the field of oncology; providing medical support in the monitoring of patients receiving medical treatments, namely remote monitoring of data indicative of the health or condition of an individual or group of individuals for medical diagnosis and treatment purposes, interactive medical monitoring and alert service for reminding clients of medical dosage, allergic sensitivity and prescription refills for medical treatment purposes; providing medical information to medial professionals in the form of analytical reports and risk classification or stratification in the field of oncology; providing medical information to patients and medical professionals in the form of reports in the field of oncology | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 10, 2026 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| May 31, 2026 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Sep 12, 2025 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Sep 11, 2025 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Mar 10, 2025 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Feb 4, 2025 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Feb 4, 2025 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Jun 11, 2024 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jun 11, 2024 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jun 11, 2024 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Apr 12, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 12, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 12, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 12, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 12, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 12, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 2, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| May 1, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 8, 2023 | NWAP | NEW APPLICATION ENTERED | — |